GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Cash Conversion Cycle

Zeo ScientifiX (Zeo ScientifiX) Cash Conversion Cycle : 93.82 (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Zeo ScientifiX's Days Sales Outstanding for the three months ended in Jan. 2024 was 3.05.
Zeo ScientifiX's Days Inventory for the three months ended in Jan. 2024 was 90.77.
Zeo ScientifiX's Days Payable for the three months ended in Jan. 2024 was 0.
Therefore, Zeo ScientifiX's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was 93.82.


Zeo ScientifiX Cash Conversion Cycle Historical Data

The historical data trend for Zeo ScientifiX's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Cash Conversion Cycle Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -521.39 -496.65 -748.68 -907.54 -1,508.55

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 229.99 144.30 196.10 93.82

Competitive Comparison of Zeo ScientifiX's Cash Conversion Cycle

For the Biotechnology subindustry, Zeo ScientifiX's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Cash Conversion Cycle falls into.



Zeo ScientifiX Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Zeo ScientifiX's Cash Conversion Cycle for the fiscal year that ended in Oct. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=2.92+201.22-1712.69
=-1,508.55

Zeo ScientifiX's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=3.05+90.77-0
=93.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zeo ScientifiX  (OTCPK:ZEOX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Zeo ScientifiX Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140

Zeo ScientifiX (Zeo ScientifiX) Headlines